Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr-Jun;13(2):100538.
doi: 10.1016/j.jaim.2021.100538. Epub 2022 Jan 4.

AYUSH- 64: A potential therapeutic agent in COVID-19

Ashok Kumar Panda  1 , Sarbeswar Kar  2 , Amit Kumar Rai  3 , B C S Rao  3 , N Srikanth  3
Affiliations
Review

AYUSH- 64: A potential therapeutic agent in COVID-19

Ashok Kumar Panda et al. J Ayurveda Integr Med. 2022 Apr-Jun.

Abstract

Corona Virus disease (COVID-19) has become a global pandemic resulting in large scale morbidity and mortality worldwide. The management of COVID-19 has been a big challenge because of multifactorial pathophysiology and no specific treatment. AYUSH-64, a poly-herbal formulation developed by CCRAS, Ministry of AYUSH, Govt. of India through extensive pharmacological, toxicological and clinical studies has proven its safety and efficacy in infective febrile conditions such as malaria and influenza. AYUSH- 64 has four ingredients having immunomodulatory, anti-inflammatory, antipyretic, antioxidant and anti-viral activities. It arrests the extreme inflammatory responses in COVID-19 that causes progression to significant morbidity. AYUSH-64 has also been incorporated in the National COVID management protocol based on Ayurveda and Yoga by Government of India for asymptomatic and mild cases of COVID-19. Further, on the basis of tangible evidence generated through robust clinical and experimental studies on AYUSH-64, the Ministry of AYUSH has launched nation-wide campaign for mass distribution of AYUSH-64 to asymptomatic, mild to moderate COVID-19 patients in home isolation to reduce the burden on the hospital. This review will highlight the specifications of AYUSH-64, its mechanism of action, its repurposing for COVID-19, various clinical and experimental studies.

Keywords: AYUSH-64; Ayurveda; COVID-19; Corona virus disease; Immunomodulation; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Clinical stages of COVID-19.
See this image and copyright information in PMC

References

    1. Dhar Chowdhury S., Oommen A.M. Epidemiology of COVID-19. J Dig Endosc. 2020;11(1):3–7. doi: 10.1055/s-0040-1712187. - DOI
    1. Jain V.K., Iyengar K.P., Vaishya R. Differences between First wave and Second wave of COVID-19 in India [published online ahead of print, 2021 May 8] Diabetes Metab. 2021;S1871–4021(21):147–148. doi: 10.1016/j.dsx.2021.05.009. - DOI - PMC - PubMed
    1. Ministry of Ayush, Government of India . 2020. National clinical management protocol based on Ayurveda and Yoga for management of Covid-19.https://www.ayush.gov.in/docs/ayush-Protocol-covid-19.pdf Available from:
    1. Chari M.V., Venkataraghavan S., Seshadri C., Shetty B.R., Gowri N. A double-blind clinical trial with Ayush-64 an Ayurvedic drug in P. vivax Malaria. J Res Ay Sid. 1982;6(3–4):105–116.
    1. Bhatia D. Role of AYUSH-64 in malaria epidemic. J Res Ay Sid. 1997;18(1- 2):71–76.